Epic Sciences, Inc.
San Diego, CA, US· latest recorded location
Epic Sciences, Inc. is named on 5 US grants and 35 published applications in this corpus. Its most frequent classification is G01N (Investigating or analysing materials by determining their chemical or physical properties).
- Granted patents
- 5
- Published applications
- 35
- Inventors
- 20
- Granted in 2026 so far
- 0
- Most recent grant
- 24 May 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2015 | 0 | 1 |
| 2016 | 0 | 4 |
| 2017 | 0 | 3 |
| 2018 | 0 | 4 |
| 2019 | 1 | 3 |
| 2020 | 3 | 3 |
| 2021 | 0 | 4 |
| 2022 | 1 | 5 |
| 2023 | 0 | 3 |
| 2024 | 0 | 2 |
| 2025 | 0 | 3 |
By publication year.
Technology areas
Share of 40 documents
- G01NInvestigating or analysing materials by determining their chemical or physical properties40
- C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms18
- A61PTherapeutic uses of medicines3
- G16BBioinformatics, i.e. information and communication technology [ict] specially adapted for genetic or3
- A61KMedicines and medical preparations2
- C07KPeptides2
Recent patents
- Methods for analyzing rare circulating cells24 May 2022US 11,340,228 B2
- Method of using non-rare cells to detect rare cells7 Apr 2020US 10,613,089 B2
- Methods for analyzing rare circulating cells28 Jan 2020US 10,545,151 B2
- Circulating tumor cell diagnostics for prostate cancer biomarkers7 Jan 2020US 10,527,624 B2
- Methods for detecting 5T4-positive circulating tumor cells and methods of diagnosis of 5T4-positive cancer in a mammalian subject9 Apr 2019US 10,254,286 B2
- Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity5 Jun 2025US 2025/0180564 A1
- Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic disease15 May 2025US 2025/0155440 A1
- Methods for the detection and quantification of circulating tumor cell mimics24 Apr 2025US 2025/0130236 A1
- Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies26 Sep 2024US 2024/0319193 A1
- Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)28 Mar 2024US 2024/0103003 A1
Most cited
By later US patents
- Methods for detecting 5T4-positive circulating tumor cells and methods of diagnosis of 5T4-positive cancer in a mammalian subject15US 10,254,286 B22019
- Circulating tumor cell diagnostics for prostate cancer biomarkers4US 10,527,624 B22020
- Methods for analyzing rare circulating cells1US 10,545,151 B22020